# First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Source: https://onco.cc/trials/nct03319628/  
OnCo record `nct03319628` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of upifitamab rilsodotin in ovarian cancer and non-small-cell lung cancer, run by Mersana Therapeutics, active and no longer recruiting.

## Summary

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b is a phase 1/2 interventional study registered as NCT03319628 by Mersana Therapeutics, with 523 participants enrolled, started 2017-12-12 and due to reach its primary completion in 2023-05-31. Interventions recorded: upifitamab rilsodotin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03319628
- Phase: 1/2
- Setting: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
- Sponsor: Mersana Therapeutics
- Enrolled: 523

## Sources

- ClinicalTrials.gov NCT03319628: https://clinicaltrials.gov/study/NCT03319628

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Mersana Therapeutics](https://onco.cc/companies/mersana/)
- drugs: [Upifitamab rilsodotin](https://onco.cc/drugs/upifitamab-rilsodotin/)

---
JSON: https://onco.cc/api/v1/entities/nct03319628.json